Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 3, 2007

Sunesis to Use CyDex Technology for Formulation of Anticancer Candidate

  • CyDex licensed its Captisol® enabling technology to Sunesis Pharmaceuticals for formulation of a selective aurora kinase inhibitor with antitumor activity across a number of nonclinical human cancer models.

    CyDex states that this technology improves water solubility, bioavailability, and complexation characteristics of insoluble and/or unstable drugs.

    Sunesis will use Captisol for the formulation of SNS-314, a selective small molecule inhibitor of aurora kinases that potently inhibits proliferation of a wide panel of human cancer cell lines. An IND has been submitted for SNS-314, and a Phase I trial for the treatment of patients with solid tumors is planned to begin in the second quarter of 2007.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »